These ten large-cap shares had been one of the best performers within the final week. Are they in your portfolio?
- Actual Sciences Company EXAS inventory escalated 26.60% after the corporate reported better-than-expected Q2 monetary outcomes and introduced an unique license settlement with TwinStrand Biosciences. A number of analysts slashed the value forecasts on the inventory.
- Alnylam Prescription drugs, Inc. ALNY shares had been up 15.35% after the corporate reported better-than-expected Q2 monetary outcomes. Analysts raised their respective worth targets on the inventory.
- Resmed Inc. RMD inventory gained 10.09% after reporting better-than-expected This fall outcomes and elevating its quarterly dividend. A number of analysts additionally raised their worth forecasts for the inventory.
- Coca-Cola Consolidated, Inc. COKE shares elevated 12.21% after the corporate reported a year-over-year improve in Q2 monetary outcomes.
- DexCom Inc.’s DXCM inventory upped 11.18% final week, bouncing again from its 52-week low.
- Sprouts Farmers Market, Inc. SFM shares elevated 11.87% after the corporate reported better-than-expected Q2 monetary outcomes and issued Q3 earnings steering above estimates. Many analysts raised their worth goal on the corporate.
- UL Options Inc. ULS inventory grew 11.74% after the corporate reported better-than-expected Q2 monetary outcomes.
- Labcorp Holdings Inc. LH inventory rose 11.34% after it reported better-than-expected Q2 monetary outcomes and raised its FY24 income steering above estimates. A number of analysts boosted their forecasts on the corporate.
- C.H. Robinson Worldwide, Inc. CHRW shares grew 10.98% after the corporate reported better-than-expected Q2 adjusted EPS outcomes. A number of corporations additionally raised their respective worth targets on the inventory.
- DoorDash Inc.’s DASH inventory gained 10.24% after the corporate reported better-than-expected Q2 income. A number of analysts raised their worth forecasts for the inventory.
Picture courtesy: Shutterstock
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.